Panelists discuss how rusfertide, a hepcidin mimetic peptide, shows promise in polycythemia vera by reducing phlebotomy ...

A panelist explains how the distinct mechanisms of erythropoiesis-stimulating agents (ESAs), luspatercept, and imetelstat ...

In the final segment, Dr. Vachhani asks Dr Rampal about emerging developments in the myeloproliferative neoplasm (MPN) field ...

A panelist emphasizes that treatment decisions for anemia in low-risk myelodysplastic syndrome should be guided by symptoms ...

Researchers explored a compelling new angle on the use of rectal spacers during prostate cancer radiotherapy, and emerging evidence suggests their benefits may extend further.

A new study reveals that rectal spacers during prostate cancer radiation therapy significantly reduce long-term erectile ...

From FDA approvals streamlining access to critical therapies to new breakthroughs in challenging malignancies, the field of cancer care continues to demonstrate remarkable progress.

Anita Turk, MD, discusses what she is most excited about regarding immunotherapy in the realm of colorectal cancer treatment.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Antonio Jimenez Jimenez, MD, discusses the ACCESS trial of PTCy-based GVHD prophylaxis after mismatched unrelated donor stem ...